SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer
Open Access
- 31 March 2016
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (1) , 39-49
Abstract
Background Intestinal metaplasia (IM) is a gastric cancer precursor lesion (GCPL) and an extremely high risk factor for progression to gastric cancer (GC). Clinical guidelines recommend that patients with extensive IM undergo a gastroscopy every 3 years. However, protein biomarkers that indicate a transition from IM to GC are lacking. Our group recently identified an interferon-alpha (IFNα)-responsive gene, Schlafen 4 (Slfn4), in immune cells that correlates with metaplastic changes in Helicobacter-infected mice. We therefore tested the hypothesis that a human homolog of Slfn4, namely, Schlafen 5 (SLFN5), correlates with progression of GCPL to GC. Methods Jurkat T-lymphoid and HL-60 myeloid cell lines were treated with IFNα, and SLFN5 mRNA was quantified by quantitative PCR. SLFN5 protein expression in the inflamed gastric mucosa was co-localized to specific immune cell types by immunohistochemistry using CD20, CD2, and MAC2 antibodies. SLFN5 expression was also determined by immunohistochemistry in formalin-fixed paraffin-embedded samples from individuals with non-atrophic gastritis, atrophic gastritis, complete IM, incomplete IM, and GC, respectively. Results The IFNα treatment of Jurkat and HL-60 cells induced SLFN5 mRNA. SLFN5 protein was expressed mainly by T lymphocytes in inflamed gastric mucosa. The highest level of SLFN5 expression was observed in patients with IM that progressed to GC. Receiver operating characteristic curves demonstrated that correlating SLFN5 expression with the histologic diagnosis of IM significantly increased the probability of identifying patients who may progress to GC. Conclusion In this study population, elevated SLFN5 protein expression in patients with IM correlated with progression to GC.Keywords
Funding Information
- National Institutes of Health (P01 DK062041)
- Instituto de Salud Carlos III (FIS Exp030077)
- RETICC, Spanish Ministry of Health (DR06/0020-0015 and PI10/01089)
- Institut d'Investigació Biomèdica de Bellvitge (PhD fellowship)
This publication has 21 references indexed in Scilit:
- The Schlafen Family of Proteins and Their Regulation by InterferonsJournal of Interferon & Cytokine Research, 2013
- Gli1 Deletion Prevents Helicobacter-Induced Gastric Metaplasia and Expansion of Myeloid Cell SubsetsPLOS ONE, 2013
- BootstRatio: A web-based statistical analysis of fold-change in qPCR and RT-qPCR data using resampling methodsComputers in Biology and Medicine, 2012
- Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)Endoscopy, 2011
- Macrophage Activation and Differentiation Signals Regulate Schlafen-4 Gene Expression: Evidence for Schlafen-4 as a Modulator of MyelopoiesisPLOS ONE, 2011
- Role of Interferon α (IFNα)-inducible Schlafen-5 in Regulation of Anchorage-independent Growth and Invasion of Malignant Melanoma CellsJournal of Biological Chemistry, 2010
- Gastric cancer occurrence in preneoplastic lesions: A long‐term follow‐up in a high‐risk area in SpainInternational Journal of Cancer, 2010
- The striking geographical pattern of gastric cancer mortality in Spain: environmental hypotheses revisitedBMC Cancer, 2009
- Oestrogen receptor status of breast carcinoma: Allred/H score conversion tableHistopathology, 2008
- Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motifInternational Immunology, 2004